Although some progress has been made in recent years with the development of more effective chemotherapy regimens, new treatment approaches are needed to improve outcomes for patients with pancreatic adenocarcinoma. The cellular process of autophagy, a cell survival mechanism that allows cancer cells to survive the hazardous conditions of the tumor microenvironment and treatment, has emerged as a viable target in pancreatic cancer. We review the mechanism of autophagy, its role in pancreatic carcinogenesis, the preclinical and clinical evidence supporting targeting autophagy in patients with pancreatic adenocarcinoma, and areas of future investigation that hold promise for improving this treatment approach.
Introduction
Pancreatic cancer is the fourth leading cause of cancer death and is estimated to be responsible for over 43 ,000 deaths in 2017. 1 Pancreatic adenocarcinoma is marked by early progression to metastatic disease and resistance to treatment. Despite recent advances in chemotherapy regimens and improvements in surgical outcomes, pancreatic cancer continues to be associated with a poor prognosis. [2] [3] [4] [5] A better understanding of the unique pancreatic cancer biology and novel targets are required to develop more efficacious treatments. The cellular process of autophagy has emerged as a key pathway promoting pancreatic carcinogenesis and resistance to therapy and represents an intriguing target to improve outcomes for pancreatic cancer patients.
Discussion

Mechanism of Autophagy
Autophagy, which means "self-eating," is a mechanism of cell survival that allows for breakdown and recycling of damaged intracellular constituents using lysosomal degradation. The process of autophagy begins with the formation of a membrane known as a phagophore that begins to sequester damaged organelles, proteins, lipids, and other intracellular components. Closure of the phagophore around the cellular components forms a double membrane called an autophagosome. The autophagosome then fuses with a lysosome, which utilizes acid hydrolase enzymes for degradation of its contents ( Figure 1 ). The breakdown products are then recycled and utilized to promote cell survival, primarily through production of adenosine triphosphate. Autophagy is utilized for cell survival under conditions when the cell is stressed or damaged. Autophagy utilizes complex molecular machinery that relies on numerous autophagy-related genes (ATGs), which were first identified in yeast. 6 Several protein markers formed or degraded during this process allow for the assessment of levels of autophagy. Cytosolic microtubule-associated protein light chain 3-I (LC3-I) is linked to phosphatidylethanolamine during formation of the autophagosome, becoming LC3-II. Thus, LC3-II represents an important marker of autophagic vesicle accumulation. 7 Additionally, cargo receptors such as p62 and NBR1 are degraded during the process of autophagy and, when considered with LC3-II levels, can provide an assessment of autophagic flux. 8 Damage-associated molecular pattern molecules (DAMP) such as high-mobility group box 1 (HMGB1) and DAMP receptors such as the receptor for advanced glycation end products (RAGE) have been implicated in pancreatic carcinogenesis through the induction of autophagy in pancreatic cancer cells. [9] [10] [11] Multiple conditions in the tumor microenvironment result in metabolic stress and therefore promote autophagy (Figure 2 ). Rapidly expanding and dividing cells quickly become nutrient deprived. They are able to utilize autophagy and other mechanisms to maintain nutrient metabolism and growth. [12] [13] [14] As tumors result of poor perfusion and high metabolic demands, promoting autophagy and cell survival. 15 Chemotherapy and radiation induce cellular damage that also results in induction of autophagy, facilitating escape from these treatments.
16-18
Rationale for Autophagy Inhibition as Treatment of Pancreatic Cancer
Autophagy is a complex cellular process that appears to serve multiple roles depending on the cancer type and physiologic context. In normal, healthy cells, autophagy may act as a tumor suppressor by clearing DNA damage and allowing the cell to correct problems before malignant transformation. 19 Beclin 1, the mammalian ortholog of yeast Atg6 and an important regulator of autophagy, is frequently underexpressed in a wide variety of human cancers. [20] [21] [22] Mice with genetic knockdown of beclin1 and other autophagy genes are more prone to tumor formation, suggesting a role for autophagy as a tumor suppressor. 23, 24 In contrast, in established cancers, autophagy is believed to promote growth by allowing cancer cells to survive metabolic stress as the pancreatic tumor microenvironment becomes hypoxic, acidotic, and nutrient deprived. 6, 25, 26 These findings support the double-edged sword of targeting autophagy in cancer, whereby the autophagy may be beneficial in preventing development of malignancy in healthy or premalignant tissues, but it promotes cancer growth in established tumors. 27, 28 For this reason, the use of autophagy inhibitors in early dysplasia or early malignancy has not been explored; rather, they have been studied in the setting of established cancer, where autophagy is thought to play a larger role in promoting tumor growth. High levels of autophagic flux correlate with poor prognosis in human pancreatic tumors. 29, 30 This correlation may be due to 
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Autophagy Inhibition in Pancreatic Adenocarcinoma autophagy facilitating resistance to chemotherapy and radiation. 26 In promoting cell survival, autophagy facilitates resistance to cell death via apoptosis. 31 By inhibiting autophagy, cancer cells can then be driven to apoptotic cell death. 11, [32] [33] [34] Therefore, the addition of autophagy inhibition to chemotherapy may improve outcomes by promoting apoptotic cell death and decreasing resistance to treatment.
Autophagy Inhibitors Studied in Pancreatic Cancer
Numerous naturally occurring compounds and synthetically derived medications have been shown to inhibit autophagy in pancreatic cancer (Table 1) . [11] [12] [13] 17, 25, 26, [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] Each of these autophagy inhibitors has a different mechanism, but they can be broadly categorized as early or late inhibitors. Early inhibitors target formation of the autophagosome, and late inhibitors target fusion of the lysosome and breakdown of components. The antimalarial drug chloroquine and a derivative, hydroxychloroquine, are the most commonly studied autophagy inhibitors in cancer, and they are the sole autophagy inhibitor to be studied in clinical trials. Hydroxychloroquine is inexpensive; further, it has high oral bioavailability and has an established safety profile thanks to its use for treatment of malaria, lupus, and rheumatoid arthritis, thus facilitating its use in patients with pancreatic cancer. 51, 52 Chloroquine functions as a lysosomal inhibitor by blocking acidification of the lysosome, thereby preventing fusion of the autophagosome, inhibiting breakdown of its contents and blocking autophagy. 53 Because it is a late inhibitor of autophagy, chloroquine treatment results in accumulation of autophagosomes and results in an increase in the autophagy marker LC3-II, with a decrease in the cargo receptors p62 and NBR1, an important consideration when monitoring LC3-II levels to evaluate treatment response.
Preclinical Studies of Autophagy Inhibition With Chloroquine in Pancreatic Cancer
Zeilhofer et al 43 Chloroquine also limits the viability of metastatic cancer cell lines, and its effects are enhanced during hypoxia. 44 Under the stress of chemotherapy, increased autophagy in cancer cells promotes resistance to therapy by facilitating cell survival. 17, 35 Therefore, inhibition of autophagy provided in combination with chemotherapy may reverse that resistance. Preclinically, chloroquine does show some activity as a single agent; however, the combination of chloroquine with chemotherapy results in even greater cytotoxicity in Panc-1 and BxPC-3 pancreatic cancer cells. 26 The benefits of chloroquine have also been shown in vivo in murine models of pancreatic cancer. Yang et al 25 demonstrated that chloroquine treatment led to a dramatic improvement in survival compared to no treatment in a mouse xenograft model, with only 1 animal of 8 chloroquinetreated mice dying of pancreatic cancer compared with all 8 mice dying of disease in the control group. A Kras-driven transgenic murine model of pancreatic adenocarcinoma was also studied, demonstrating that chloroquine led to a statistically significant increase in survival compared to no treatment. Mirzoeva et al 33 showed that autophagy suppression with chloroquine decreased tumor growth in murine pancreatic adenocarcinoma xenografts when provided in combination with a phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) dual target inhibitor. These preclinical studies supported the development of clinical trials that target autophagy using chloroquine and its derivative, hydroxychloroquine, as treatment targeting pancreatic cancer.
Neoadjuvant Clinical Trials of Autophagy Inhibition in Pancreatic Cancer
Hydroxychloroquine remains the only autophagy inhibitor evaluated in clinical trials thus far, likely because its use to treat malaria, rheumatoid arthritis, and lupus, thus demonstrating its safety, facilitated its evaluation in cancer. Published and currently ongoing trials listed on the National Institutes of Health Clinical Trials Registry are provided in Table 2. 54-56 A phase 1/2 doseescalation trial of preoperative hydroxychloroquine with gemcitabine in patients with localized pancreatic adenocarcinoma was published in 2015. 54 Thirty-five patients were treated with 30 days of hydroxychloroquine continued until the day of surgery with 2 doses of fixed-dose gemcitabine. Using a Storer design for the dose escalation phase of the trial, one patient was treated at each lower dose up to the maximum tolerated dose of 1200 mg per day. The treatment was safe and tolerable, with no grade IV or V treatmentrelated events. Sixty-one percent of patients demonstrated a CA19-9 response to treatment, and 77% went on to R0 resection. These results were better than historical controls from a previously published cohort study of the same patient population. Furthermore, patients who had a CA19-9 response to treatment had improved overall and disease-free survival, suggesting biologic activity of the treatment regimen. Another neoadjuvant study from the same institution recently completed accrual, with encouraging preliminary results presented at the annual meeting of the Society of Surgical Oncology. 57 This was a phase 2 randomized study of gemcitabine with nab-paclitaxel with or without hydroxychloroquine as preoperative therapy for patients with pancreatic adenocarcinoma. Publication of the final results of the trial is forthcoming, but preliminary analysis showed that treatment with hydroxychloroquine resulted in improvements in pathologic treatment response, CA19-9 response, and lymph node ratio, which are encouraging surrogate end points for survival.
58-60
Metastatic Clinical Trials of Autophagy Inhibition in Pancreatic Cancer
Wolpin et al 55 performed a phase 2 clinical study of single-agent hydroxychloroquine in patients with metastatic pancreatic cancer whose disease failed to respond to prior treatment. Twenty patients were treated with 2 doses of hydroxychloroquine, 400 mg and 600 mg, provided twice daily; both doses were well tolerated with minimal toxicity. Levels of the autophagy marker LC3-II were measured in peripheral lymphocytes on the basis of preclinical support for this strategy in murine models, but inconsistent evidence of autophagy inhibition was demonstrated. The treatment resulted in minimal clinical activity, with only 10% of patients without progressive disease at 2 months. The median overall survival was 69 days. The short survival seen in the study may have been due to the advanced disease stage of patients in the trial, thus necessitating a short course of therapy. It is important to consider that patients enrolled onto this trial had poor performance status (those with Eastern Cooperative Oncology Group score of 2 were included) and in terminal stages of illness; a more robust response may have been recognized in patients with an earlier stage of disease. The results of this trial are, however, consistent with the preclinical data, suggesting little effect of chloroquine and other autophagy inhibitors as monotherapy. Combination treatment with chemotherapy may be more effective, as chemotherapy promotes the tumors' reliance on autophagy.
26,42,45
Emerging Literature on Autophagy in Gastrointestinal Cancers
In addition to the encouraging research into autophagy in pancreatic cancer, recent literature has supported the antitumor effects of autophagy inhibition in other gastrointestinal cancers. Higher levels of autophagic markers were recently discovered to be associated with poor prognosis in patients with colon cancer. 61 In a phase 1 trial of patients with advanced solid tumors, of which w15% were colorectal cancer patients, hydroxychloroquine was combined with the mTOR inhibitor temsirolimus, demonstrating that this combination was safe and had anticancer activity. 56 Another trial, which evaluated hydroxychloroquine with the histone deacetylase inhibitor vorinostat in advanced solid tumors, also enrolled patients with colorectal cancer. 62 This combination was found to be safe and had preliminary evidence of efficacy. In addition to these early-phase clinical trials, ongoing laboratory-based translational research efforts continue to further elucidate the role of autophagy and its inhibition as a treatment strategy in gastrointestinal cancers, particularly gastric and colorectal cell lines and animal models. [63] [64] [65] [66] Much of this important work in gastrointestinal cancers can be translated to further expand our understanding of the role, mechanism, and treatment impact of autophagy in pancreatic cancer.
Future Directions for Autophagy Research
The early success of preclinical and clinical studies of autophagy inhibition in pancreatic cancer supports further research into many areas related to autophagy that warrant further investigation. Investigation into additional drugs targeting autophagy has resulted in discovery of new agents that hold promise for treatment of pancreatic cancer, including many that have been studied in preclinical models. 67 EAD1 is a synthesized chloroquine analog that is 8 times more potent than chloroquine in inhibiting proliferation of pancreatic cancer cells. 46 Deguelin is a naturally occurring plant extract that inhibits autophagy in pancreatic cancer cells and sensitizes to doxorubicin. 45 IMB-6G is a synthesized derivative of a herbal extract sophoridine that causes lysosomal dysfunction, resulting in autophagosome accumulation and autophagy inhibition, thereby inducing apoptosis in pancreatic cancer cell lines. 48 Lumican is a proteoglycan secreted into the tumor microenvironment by pancreatic stellate cells that inhibits autophagy and enhances effects of chemotherapy. 36 Verteporfin is an early autophagy inhibitor that prevents autophagosome accumulation, reduces tumor growth, and enhances survival when combined with gemcitabine in a mouse xenograft model. 42 Lys05, a water-soluble salt more potent than chloroquine, has shown antitumor activity as a single agent in multiple human cancer cell lines and murine tumor models. 68, 69 DQ661 is an inhibitor of palmitoyleprotein thioesterase 1 (PPT1), which, when blocked, impairs both mTOR signaling and lysosomal catabolism to inhibit autophagy. 70 DQ661
has demonstrated efficacy in murine models of pancreatic and colorectal cancer. 70 In addition to enhancing the efficacy of chemotherapy, autophagy inhibitors may also contribute to the effectiveness of targeted therapy. The addition of macrolide antibiotics known to inhibit autophagy, clarithromycin and azithromycin, to an epidermal growth factor receptor tyrosine kinase inhibitor induced cell death by blocking autophagic flux. 49 Mitogen-activated protein kinase and nuclear factor kappaelight-chain enhancer of activated B cells (NF-kB) inhibition triggers apoptosis when combined with autophagy inhibitors. 37 The addition of autophagy inhibition promotes apoptosis in response to PI3K/mTOR inhibitors. 33 GDC-0980, a novel PI3K/mTOR inhibitor, resulted in enhanced apoptosis when combined with autophagy inhibition. 38 A seaweed (Fucus vesiculosus) extract demonstrated killing effects in pancreatic cancer cell lines that were enhanced when combined with autophagy inhibitors. 39 Inhibition of autophagy strengthened celastrol-induced apoptosis in vitro and in vivo in pancreatic ductal adenocarcinoma. 40 Although preclinical models have shown a benefit to autophagy inhibition, the optimal drug to block autophagy and the ideal regimen to combine it with remain areas of active investigation.
Biomarkers that predict response to treatment are desperately needed in pancreatic cancer to maximize treatment effect in select patients. Oncogenic RAS, a key mutation in pancreatic cancer that regulates autophagic flux, has been studied to predict patients who are most likely to benefit from therapy with autophagy inhibition. 71 Unfortunately, the induction of autophagy by RAS in pancreatic cancer cell lines was found to be context dependent, and the mutation status of RAS could not predict benefit to chloroquine. Measurement of the autophagy marker LC3-II in peripheral blood lymphocytes has demonstrated promise as a measure of autophagy inhibition and could potentially be used to select patients for therapy and monitor treatment response. In a neoadjuvant trial of hydroxychloroquine in pancreatic cancer, patients who had a larger increase in LC3-II consistent with greater autophagy inhibition demonstrated improved disease-free and overall survival, suggesting that autophagy inhibition contributed to outcomes. 54 However, in the clinical trial of 20 patients with metastatic pancreatic adenocarcinoma treated with hydroxychloroquine, LC3-II measures in peripheral blood demonstrated inconsistent evidence of autophagy inhibition. 55 Further exploration into molecular characteristics or other factors to determine patients most likely to benefit from therapy is required. In addition to directly targeting autophagy's role in cancer cell survival, there are other downstream autophagy-mediated pathways that also contribute to pancreatic carcinogenesis that are actively being investigated. Autophagy has a role not only promoting survival directly in tumor cells, but also in other cells that contribute to cancer development and growth. After first being described in sepsis and infection, neutrophil extracellular traps (NETs) have recently been implicated in cancer, including in pancreatic cancer. 72 NETs occur when activated neutrophil release DNA, histones, granules, and other proteins in the extracellular space or circulation. NETs have been shown to promote tumor growth, 73 development of metastases, 74, 75 and tumor-associated thrombosis. 76, 77 Autophagy is required for NET formation. 72 Therefore, targeting autophagy also inhibits NETs, limiting the effects of NETs in pancreatic cancer.
A dense desmoplastic stroma is characteristic of the pancreatic cancer tumor microenvironment. Autophagy affects not only cancer cells but also the cells in the tumor stromal microenvironment, which promotes an inflammatory response that promotes tumor growth and resistance to treatment. 78 Pancreatic stellate cells are the primary cells in the stromal tumor microenvironment, and they produce extracellular matrix molecules and cytokines that form the dense fibrotic stroma that is the hallmark of pancreatic cancer. Pancreatic stellate cells collected from patients with pancreatic cancer have elevated levels of autophagy, with higher amounts of autophagy being associated with worse prognosis. 79 Inhibitors of autophagy decreased extracellular matrix molecular production in pancreatic stellate cells. Autophagy inhibition in pancreatic stellate cells that were then injected in tumor-bearing mice resulted in smaller tumors with fewer liver metastases and less peritoneal dissemination. One mechanism by which pancreatic stellate cell autophagy contributes to tumor growth is through the release of alanine, which is utilized for tumor cell metabolism. 80 Pancreatic cancer stem cells are thought to be responsible for tumor initiation and growth, and eradication of pancreatic cancer may require treatments that target these stem cells. 81 Autophagy also occurs in cancer stem cells and promotes their survival during treatment. Elevated levels of autophagy in pancreatic stem cells are associated with poor outcome. 47 Inhibition of autophagy results in decreased stem cell activity and improves efficacy of chemotherapy. These studies suggest that targeting autophagy in pancreatic cancer not only provides a benefit by decreasing survival, promoting apoptosis, and inhibiting resistance to treatment in tumor cells but may also target other pathways that contribute to tumor progression that also rely on autophagy. Neutrophil trap formation, pancreatic stellate cells, and pancreatic stem cells all rely on autophagy and represent novel targets for autophagy inhibition. Further research into the role of autophagy in these and other cancer-associated processes is warranted and holds promise for improving outcomes.
Conclusion
Autophagy inhibition represents a novel treatment approach in pancreatic cancer that augments treatment with traditional chemotherapy. Preliminary studies support the use of autophagy inhibitors in pancreatic cancer. Further studies to identify and evaluate more effective autophagy inhibitors and to better understand the mechanisms and role of autophagy in pancreatic cancer are warranted.
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